Enhanced CAR-T Cell Therapy with Artificial Antigenic Epitope
Legal Citation
Summary of the Inventive Concept
An improved CAR-T cell therapy approach utilizing an optimized artificial antigenic epitope to enhance central memory T cell (Tcm) yield, persistence, and therapeutic efficacy, addressing limitations in existing CAR-T cell manufacturing and treatment.
Background and Problem Solved
The original patent, 'Method for preparing CAR-T cell with TCM as main active component and use thereof,' demonstrated the potential of CAR-T cell therapy using central memory T cells (Tcm). However, the existing approach faces challenges in achieving high Tcm yields, persistence, and therapeutic efficacy. The new inventive concept addresses these limitations by introducing an optimized artificial antigenic epitope, strategically located in the extracellular domain of the CAR, to enhance Tcm activation, growth, and survival.
Detailed Description of the Inventive Concept
The enhanced CAR-T cell therapy approach comprises a CAR with an artificial antigenic epitope optimized for binding affinity, located in the extracellular domain. This epitope selectively activates Tcm cells, promoting their growth, differentiation, and survival. The system further includes a bioreactor with a controlled environment for optimized Tcm cell growth and differentiation. Additionally, the invention encompasses a method for monitoring CAR-T cell therapy by detecting the expression of a biomarker associated with Tcm cell activation. This biomarker is selectively induced by the artificial antigenic epitope, enabling real-time assessment of therapy efficacy.
Novelty and Inventive Step
The new inventive concept introduces an optimized artificial antigenic epitope, strategically located in the extracellular domain of the CAR, which enhances Tcm activation, growth, and survival. This epitope, combined with the controlled bioreactor environment and biomarker-based monitoring, provides a novel and non-obvious solution to the limitations of existing CAR-T cell therapy approaches.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the location of the artificial antigenic epitope within the CAR, using different types of antigen-presenting cells, or incorporating additional biomarkers for monitoring therapy efficacy. These variations can be implemented to broaden the scope of the inventive concept and adapt to diverse therapeutic applications.
Potential Commercial Applications and Market
The enhanced CAR-T cell therapy approach has significant commercial potential in the treatment of various cancers, including hematological malignancies and solid tumors. The target market includes pharmaceutical companies, biotechnology firms, and hospitals, with potential applications in personalized medicine, regenerative medicine, and immunotherapy.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, specifically CAR-T cell engineering and cell therapy manufacturing with a focus on central memory T cell (Tcm) manipulation and activation strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced degrees in immunology, molecular biology, or bioengineering, possessing expertise in T cell engineering, cell therapy design, and CAR-T cell manufacturing techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's modifications to CAR-T cell design represent predictable engineering variations that extend the core teachings of the source patent. The strategic placement of an artificial antigenic epitope in the CAR's extracellular domain and the associated manufacturing and monitoring techniques are logical extensions of existing CAR-T cell development approaches. These variations demonstrate incremental improvements that would be apparent to a skilled practitioner seeking to optimize Tcm cell activation and therapeutic efficacy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,572 |
|---|---|
| Title | Method for preparing CAR-T cell with TCM as main active component and use thereof |
| Assignee(s) | Xuanwu Hospital Capital Medical University |